510(k) device
Aeye-Ds
Aeye Health, Inc. · Diabetic Retinopathy Detection Device (PIB, Class II) · First FDA decision Nov 10, 2022, newest Apr 23, 2024DiabetesMacular degeneration and retinal disease
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
3
Naming "Aeye-Ds"
MAUDE reports
1
Brand "Aeye-Ds", since 2015
PubMed studies
4
Mentioning "Aeye-Ds"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Aeye-Ds
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- AEYE-DS510(k)
K240058 · Decided Apr 23, 2024 · 106 days after receipt
Device type: Diabetic Retinopathy Detection Device (PIB) · Ophthalmology
- AEYE-DS510(k)
K221183 · Decided Nov 10, 2022 · 199 days after receipt
Device type: Diabetic Retinopathy Detection Device (PIB) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Aeye-Ds", any status and sponsor, newest update first.
AEYE Health IncNot on our public-company list
NCT06241664 · 601 participants · Start Jan 31, 2024 · Primary completion Oct 2, 2024
Device: AEYE-DS Software · For: Diabetic Retinopathy, DR; Diabetic Mellitus
Sites: Houston, Texas
AEYE Health IncNot on our public-company list
NCT05857943 · 363 participants · Start Mar 29, 2023 · Primary completion Sep 11, 2023
Device: AEYE-DS Software · For: Diabetes Mellitus; Diabetic Retinopathy
Sites: Fayetteville, Arkansas; Orlando, Florida; Jackson, Tennessee
- Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Fundus ImagesPivotal-lookingCompleted
AEYE Health IncNot on our public-company list
NCT04612868 · 531 participants · Start Oct 16, 2020 · Primary completion Nov 28, 2021
Device: AEYE Software Device · For: Diabetes Mellitus; Diabetic Retinopathy
Sites: Louisville, Kentucky
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Aeye-Ds", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 1 injury, 0 death
Whole product code PIB
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
- AEYE-DS RETINA SCREENINGInjury
MW5165159 · Received Jan 22, 2025 · Event dated Dec 18, 2024
Device type: Diabetic Retinopathy Detection Device (PIB)
Patient problem as coded: Glaucoma; Intraocular Pressure Increased
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Aeye-Ds"[tiab]. The summary above synthesizes these.
- Autonomous Artificial Intelligence in Diabetic Retinopathy Testing-Lessons Learned on Successful Health System Adoption.
Teng CW, Patel SD, Barkmeier AJ, et al. · Ophthalmol Sci · 2026
- Leveraging Artificial Intelligence for Diabetic Retinopathy Screening and Management: History and Current Advances.
Rajalakshmi R, PramodKumar TA, Naziyagulnaaz AS, et al. · Semin Ophthalmol · 2025Review
- Autonomous AI-driven point-of-care screening for diabetic retinopathy compared to reading center multi-expert clinical review: results from three prospective controlled pivotal validation studies with AEYE-DS in over 1,200 patients.
Dvey-Aharon Z, Livne M, Margalit D, et al. · Front Digit Health · 2026
- Real-world integration of an autonomous artificial intelligence system for diabetic retinopathy screening in an endocrinology outpatient clinic.
Gil O, Arad A, Fogel M, et al. · Br J Ophthalmol · 2026
Other devices of this type
Also filed under product code PIB.
- iPredict-DRiHealthscreen, Inc. · 510(k) 2026
- EyeArt v2.2.0Eyenuk, Inc. · 510(k) 2023
- IDx-DR v2.3Digital Diagnostics, Inc. · 510(k) 2022
- IDx-DRDigital Diagnostics, Inc. · 510(k) 2021
- EyeArtEyenuk, Inc. · 510(k) 2020
- IDx-DRIdx, LLC · De Novo 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.